Recent Events – Safe Biologics

ASBM Representatives Discuss Biosimilars on AI Arthritis Podcast

September 3, 2022

On August 31st, several ASBM representatives joined Tiffany Westrich-Robertson, CEO of the International Foundation for Autoimmune & Autoinflammatory Diseases, to record an episode of the AI Arthritis Voices 360 podcast. The episode discussed examined policy issues surrounding biosimilars and how these affect patients. ASBM was represented in the discussion by Executive Director Michael Reilly; Chairman Ralph McKibbin, […]

ASBM Chair Presents Poster on US Physician Survey at DIA Global Annual Meeting 2022

June 24, 2022

On June 20th, ASBM Chairman Ralph McKibbin, MD, FACP, FACG, AGAF presented a poster at the DIA Global Annual Meeting 2022 in Chicago, IL. The poster was entitled “U.S. Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” and featured results from ASBM’s 2021 survey of 401 U.S. physicians. Among its key findings: Nearly all physicians surveyed expressed […]

ASBM Presents Fourth 5-Hour CE Course to NY Pharmacists

February 29, 2020

On February 23rd, ASBM presented a Continuing Education (CE) course entitled “Biosimilars- What’s New in 2020?” to a class consisting of more than 75 New York area pharmacists. The event took place at the LaGuardia Marriott in East Elmhurst, NY and was hosted by Long Island University College of Pharmacy (LIU-Pharmacy). This is the fourth time ASBM has […]

ASBM Chairs Past and Present, Four Steering Committee Members Testify at FDA Biosimilar Hearing

September 13, 2018

On September 4th, 2018, the U.S. Food and Drug Administration (FDA) held a hearing on the Biosimilar Action Plan announced by FDA Commissioner Scott Gottlieb in July. The action plan addressed 4 key areas intended to improve biosimilar competition: Improving the efficiency of the biosimilar and interchangeable product development and approval process Maximizing scientific and regulatory clarity […]

ASBM Chairs Past and Present, Four Steering Committee Members Testify at FDA Biosimilar Hearing

September 13, 2018

On September 4th, 2018, the U.S. Food and Drug Administration (FDA) held a hearing on the Biosimilar Action Plan announced by FDA Commissioner Scott Gottlieb in July. The action plan addressed 4 key areas intended to improve biosimilar competition: Improving the efficiency of the biosimilar and interchangeable product development and approval process Maximizing scientific and regulatory clarity […]

ASBM Hosts Naming Roundtable With WHO, FDA, Health Canada

July 13, 2018

On July 12, in Washington, DC the Alliance for Safe Biologic Medicines (ASBM) hosted the second in a series of meetings to discuss the global harmonization of nomenclature for biologic and biosimilar medicines. Representatives from the World Health Organization, the U.S. Food and Drug Administration (FDA), Health Canada, the United States Pharmacopeia (USP), and the American […]

ASBM Exhibits at DIA 2018 Conference

June 30, 2018

From June 25-27, ASBM exhibited at the 2018 Drug Industry Association Conference (DIA 2018). ASBM was represented at DIA by Chair Madelaine Feldman MD, FACR and Advisory Board Chair Philip Schneider, MS FASHP. In addition to meeting attendees at ASBM’s booth, Drs. Feldman and Schneider attended several panels related to biosimilar policy, and engaged participants […]

ASBM Exhibits at DIA 2018 Conference

June 30, 2018

From June 25-27, ASBM exhibited at the 2018 Drug Industry Association Conference (DIA 2018). ASBM was represented at DIA by Chair Madelaine Feldman MD, FACR and Advisory Board Chair Philip Schneider, MS FASHP. In addition to meeting attendees at ASBM’s booth, Drs. Feldman and Schneider attended several panels related to biosimilar policy, and engaged participants […]

ASBM Presents on Naming at World Biosimilar Congress USA 2018

June 12, 2018

On May 24th, ASBM presented at the World Biosimilars Congress USA 2018 in San Diego, CA. The theme of the two-day conference was “Helping the global industry bring biosimilars to the US” and it drew more than 100 attendees including representatives from the industry, health care professionals, and payers. ASBM Advisory Chair Philip Schneider gave a presentation […]

ASBM Presents on Naming at World Biosimilar Congress USA 2018

June 12, 2018

On May 24th, ASBM presented at the World Biosimilars Congress USA 2018 in San Diego, CA. The theme of the two-day conference was “Helping the global industry bring biosimilars to the US” and it drew more than 100 attendees including representatives from the industry, health care professionals, and payers. ASBM Advisory Chair Philip Schneider gave a presentation […]